Go to deals
Healthcare

Protalix BioTherapeutics, Inc. has completed a private stock placement

Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.

Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.

Talk to the deal team

 Boaz  Levi

Boaz Levi

Partner
Tel Aviv, Israel
Oaklins Rosario

Related deals

Nordian Capital has raised debt to acquire Wetac
Private Equity | Energy

Nordian Capital has raised debt to acquire Wetac

Nordian Capital, a Netherlands-based private equity firm, has joined the shareholder base of Wetac Battery Company (Wetac), a leading supplier of batteries, battery systems and accessories for various applications and end markets. The financing was provided by OLB and will support Wetac’s strong growth ambitions.

Learn more
A group of Chilean investors has acquired Farmacias Ahumada
Consumer & Retail | Healthcare

A group of Chilean investors has acquired Farmacias Ahumada

A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.

Learn more
Expice has been acquired by Betronic
Industrial Machinery & Components

Expice has been acquired by Betronic

Betronic B.V. has raised acquisition financing provided by Rabobank to support the acquisition of Expice.

Learn more